journal
https://read.qxmd.com/read/38340290/helicobacter-pylori-eradication-treatment-in-older-patients
#21
REVIEW
Paulius Jonaitis, Juozas Kupcinskas, Javier P Gisbert, Laimas Jonaitis
Helicobacter pylori is the main etiopathogenetic factor of chronic gastritis, peptic ulcer disease and gastric cancer. The world's population is shifting towards older people, who have the highest prevalence of H. pylori. Aging-related peculiarities could have an impact on the treatment of H. pylori and there is still a lack of research data in the older population. The aim of this review was to summarize the findings of the most recent information, publications and studies on the issues relating to H. pylori infection in older patients...
February 2024: Drugs & Aging
https://read.qxmd.com/read/37880500/nsaids-for-pain-control-during-the-peri-operative-period-of-hip-fracture-surgery-a-systematic-review
#22
Wilhelm Pommier, Elise-Marie Minoc, Pierre-Marie Morice, Pascale Lescure, Cyril Guillaume, Claire Lafont, Marc-Olivier Fischer, Jacques Boddaert, Sara Thietart, Véronique Lelong-Boulouard, Bérengère Beauplet, Cédric Villain
BACKGROUND: Hip fracture (HF) mostly affects older adults and is responsible for increased morbidity and mortality. Non-steroidal anti-inflammatory drugs (NSAIDs) are part of the peri-operative multimodal analgesic management, but their use could be associated with adverse events in older adults. This systematic review aimed to assess outcomes associated with NSAIDs use in the peri-operative period of HF surgery. METHODS: This systematic review was conducted according to the PRISMA guidelines...
February 2024: Drugs & Aging
https://read.qxmd.com/read/38165603/comment-on-patient-perceptions-of-opioids-and-benzodiazepines-and-attitudes-toward-deprescribing
#23
LETTER
Aili V Langford, Carl R Schneider, Emily Reeve, Jason N Doctor, Danijela Gnjidic
No abstract text is available yet for this article.
January 2024: Drugs & Aging
https://read.qxmd.com/read/37991658/cutaneous-lupus-erythematosus-review-and-considerations-for-older-populations
#24
REVIEW
Briana Heinly, Astia Allenzara, Matthew Helm, Galen T Foulke
Though more common earlier in life, increasing attention is being focused on the development of cutaneous lupus erythematosus (CLE) in patients with advancing age. Studies show that CLE is more common in older populations than previously thought, and all CLE subtypes are possible in this group. Just like patients in the third or fourth decade of life, CLE may appear alongside or independent of systemic lupus erythematosus. Older populations manifesting CLE for the first time seem to have a lower risk of progression to systemic disease than younger peers, and are more commonly White...
January 2024: Drugs & Aging
https://read.qxmd.com/read/37982982/evaluating-the-safety-of-an-educational-deprescribing-intervention-lessons-from-the-optimize-trial
#25
RANDOMIZED CONTROLLED TRIAL
Cynthia M Boyd, Susan M Shetterly, John D Powers, Linda A Weffald, Ariel R Green, Orla C Sheehan, Emily Reeve, Melanie L Drace, Jonathan D Norton, Mahesh Maiyani, Kathy S Gleason, Jennifer K Sawyer, Matthew L Maciejewski, Jennifer L Wolff, Courtney Kraus, Elizabeth A Bayliss
BACKGROUND: Patients, family members, and clinicians express concerns about potential adverse drug withdrawal events (ADWEs) following medication discontinuation or fears of upsetting a stable medical equilibrium as key barriers to deprescribing. Currently, there are limited methods to pragmatically assess the safety of deprescribing and ascertain ADWEs. We report the methods and results of safety monitoring for the OPTIMIZE trial of deprescribing education for patients, family members, and clinicians...
January 2024: Drugs & Aging
https://read.qxmd.com/read/38127166/correction-to-prevalence-and-factors-associated-with-inappropriate-dosing-of-apixaban-and-rivaroxaban-in-hospitalized-older-adults-with-atrial-fibrillation-a-cross%C3%A2-sectional-study
#26
Théodore Decaix, Kenza Kemache, Pierre Gay, Olivier Laprévote, Flora Ketz, Éric Pautas
No abstract text is available yet for this article.
December 21, 2023: Drugs & Aging
https://read.qxmd.com/read/38123766/individualized-dosing-patterns-in-the-treatment-of-older-patients-with-gastrointestinal-stromal-tumors-results-of-a-registry-based-observational-national-cohort-study-including-871-patients
#27
JOURNAL ARTICLE
Roos F Bleckman, K Esther Broekman, Evelyne Roets, Mohammed Mohammadi, Ingrid M E Desar, Hans Gelderblom, Ron H J Mathijssen, Neeltje Steeghs, Pauline de Graeff, Anna K L Reyners
BACKGROUND: While the effectiveness of tyrosine kinase inhibitors (TKIs) seems similar in older patients with gastrointestinal stromal tumors (GIST) compared with younger patients, toxicities in older patients treated with TKIs more often lead to discontinuation of treatment. OBJECTIVE: To better understand the age-related pharmacology and pharmacodynamic differences in patients with GIST treated with TKIs, the primary aim of this study was to evaluate TKI dosing patterns in older patients with GIST, while the secondary aims were to evaluate differences in imatinib trough plasma concentrations between age groups and to compare the overall survival (OS) in patients with and without dose reductions in all treatment lines in a palliative setting...
December 20, 2023: Drugs & Aging
https://read.qxmd.com/read/38114724/do-proton-pump-inhibitors-reduce-upper-gastrointestinal-bleeding-in-older-patients-with-atrial-fibrillation-treated-with-oral-anticoagulants-a-nationwide-cohort-study-in-france
#28
JOURNAL ARTICLE
Solene Drusch, Anke Neumann, Hugues Michelon, Marion Pépin, Mahmoud Zureik, Marie Herr
BACKGROUND: Proton pump inhibitors (PPIs) are largely used in older adults and data are needed in off-label indications, such as the prevention of upper gastrointestinal bleeding (UGIB) in patients receiving oral anticoagulants (OACs). This study aimed to assess whether PPIs reduce the risk of UGIB in patients initiating oral anticoagulation. METHODS: We conducted a longitudinal study based on the French national health database. The study population included 109,693 patients aged 75-110 years with a diagnosis of atrial fibrillation who initiated OACs [vitamin K antagonist (VKA) or direct OAC (DOAC)] between 2012 and 2016...
December 20, 2023: Drugs & Aging
https://read.qxmd.com/read/37943474/factors-associated-with-psychotropic-medication-use-in-people-living-with-dementia-in-the-community-a-systematic-review-and-meta-analysis
#29
Kerryn L Loftus, Anne P F Wand, Juanita L Breen, Glenn E Hunt, Carmelle Peisah
BACKGROUND: There has been considerable focus on the use of psychotropic agents in people living with dementia in long-term care. However, psychotropic use often commences well before transitioning to long-term care. OBJECTIVES: To synthesize the available literature to identify factors associated with psychotropic medication use in people living with dementia in the community. METHODS: This PROSPERO-registered review reports findings from a comprehensive search of Embase, PsycINFO, and PubMed (including MEDLINE) databases according to predefined inclusion and exclusion criteria (2010-2022)...
December 2023: Drugs & Aging
https://read.qxmd.com/read/38036916/potentially-inappropriate-psychotropic-drugs-in-nursing-homes-an-italian-observational-study
#30
JOURNAL ARTICLE
Marina Azab, Alessio Novella, Aladar Ianes, Luca Pasina
BACKGROUND AND OBJECTIVES: Physicians often face difficulties in selecting appropriate medications for older adults with multiple comorbidities. As people age, they are more likely to be living with a number of chronic conditions (multimorbidity) and be prescribed a high number of medications (polypharmacy). Multimorbidity is frequent in nursing home (NH) residents and the use of potentially inappropriate medications, especially psychotropic drugs, is widespread. This retrospective cross-sectional cohort study examined the frequency of potentially inappropriate psychotropic drugs using the Beers, Screening Tool of Older Persons' Prescriptions/Screening Tool to Alert doctors to Right Treatment (STOPP/START) and Fit fOR The Aged (FORTA) criteria, and their association with mortality...
November 30, 2023: Drugs & Aging
https://read.qxmd.com/read/37991657/a-trial-based-cost-utility-analysis-of-a-medication-optimization-intervention-versus-standard-care-in-older-adults
#31
JOURNAL ARTICLE
Eirin Guldsten Robinson, Hanna Gyllensten, Jeanette Schultz Johansen, Kjerstin Havnes, Anne Gerd Granas, Trine Strand Bergmo, Lars Småbrekke, Beate Hennie Garcia, Kjell H Halvorsen
BACKGROUND: Older adults are at greater risk of medication-related harm than younger adults. The Integrated Medication Management model is an interdisciplinary method aiming to optimize medication therapy and improve patient outcomes. OBJECTIVE: We aimed to investigate the cost effectiveness of a medication optimization intervention compared to standard care in acutely hospitalized older adults. METHODS: A cost-utility analysis including 285 adults aged ≥ 70 years was carried out alongside the IMMENSE study...
November 22, 2023: Drugs & Aging
https://read.qxmd.com/read/37976015/potentially-inappropriate-prescribing-in-multimorbid-and-polymedicated-older-adults-with-af-a-systematic-review-and-meta-analysis
#32
Cheima Amrouch, Delphine Vauterin, Souad Amrouch, Maxim Grymonprez, Lu Dai, Cecilia Damiano, Amaia Calderón-Larrañaga, Lies Lahousse, Dirk De Bacquer, Gregory Y H Lip, Davide L Vetrano, Delphine De Smedt, Mirko Petrovic
AIM: Polypharmacy in multimorbid older patients with atrial fibrillation (AF) is a risk factor for potentially inappropriate prescribing (PIP). We aimed to systematically assess the evidence on the prevalence of PIP and its impact on adverse health outcomes in this patient group. METHODS: A systematic search of the published peer-reviewed literature describing the prevalence of PIP and/or its association with adverse health outcomes in multimorbid (AF plus one comorbidity) and polymedicated (≥ 2 drugs) adults ≥ 65 years was done up to March 2023...
November 17, 2023: Drugs & Aging
https://read.qxmd.com/read/37957440/prevalence-and-factors-associated-with-inappropriate-dosing-of-apixaban-and-rivaroxaban-in-hospitalized-older-adults-with-atrial-fibrillation-a-cross-sectional-study
#33
JOURNAL ARTICLE
Théodore Decaix, Kenza Kemache, Pierre Gay, Olivier Laprévote, Flora Ketz, Éric Pautas
INTRODUCTION: Atrial fibrillation (AF) is a common condition among older adults, requiring anticoagulation therapy to prevent thromboembolic events. Direct oral anticoagulants (DOACs) are now recommended as first-line therapy for this purpose. Apixaban and rivaroxaban are two direct-factor Xa inhibitors whose dosing is based on various factors (age, weight, creatinine, and creatinine clearance) that can affect the pharmacokinetics of the medication. This study aimed to evaluate factors associated with inappropriate dosing of apixaban or rivaroxaban based on the summary of product characteristics...
November 13, 2023: Drugs & Aging
https://read.qxmd.com/read/37955833/acknowledgement-to-referees
#34
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
November 13, 2023: Drugs & Aging
https://read.qxmd.com/read/37938521/polypharmacy-and-antibody-response-to-sars-cov-2-vaccination-in-residents-of-long-term-care-facilities-the-gerocovid-vax-study
#35
JOURNAL ARTICLE
Caterina Trevisan, Labjona Haxhiaj, Alba Malara, Angela Abbatecola, Giorgio Fedele, Annapina Palmieri, Pasqualina Leone, Ilaria Schiavoni, Paola Stefanelli, Stefania Maggi, Giuseppe Sergi, Stefano Volpato, Raffaele Antonelli Incalzi, Graziano Onder
BACKGROUND AND OBJECTIVE: Polypharmacy is common in older adults, particularly among those living in long-term care facilities. This condition represents a marker of clinical complexity and might directly affect the immunological response. However, there are limited data on the association of polypharmacy with vaccine immunogenicity. This study evaluated the immune response to anti-SARS-CoV-2 vaccines in older residents of long-term care facilities as a function of the number of medications used...
November 8, 2023: Drugs & Aging
https://read.qxmd.com/read/37755662/the-promising-project-a-pilot-study-to-improve-geriatric-care-through-a-pharmacist-led-psychotropic-stewardship-program
#36
JOURNAL ARTICLE
Marie d'Amours, Farah Ettis, Lauriane Ginefri, Johnny Lim, Angela-Sinlan Lin Poo Yuan, Jennifer Fontaine, Dana Wazzan, David Williamson, Vincent Dagenais-Beaulé
BACKGROUND AND OBJECTIVE: Psychotropic medications are frequently prescribed during acute care, even in older patients. They represent a risk for inappropriate long-term use and increase the overall risk of morbidity and mortality in this population. Our project aimed to evaluate the feasibility of a psychotropic medication stewardship program led by pharmacists. METHODS: We conducted a prospective, observational pilot study in patients aged 75 years and older, admitted to a surgical unit with at least one active prescription of a psychotropic medication (antipsychotic, benzodiazepine or non-benzodiazepine receptor agonist)...
November 2023: Drugs & Aging
https://read.qxmd.com/read/37902947/current-pharmacological-therapies-for-the-management-of-spondyloarthritis-special-considerations-in-older-patients
#37
REVIEW
Renaud Felten, Eric Toussirot
Spondylarthritis (SpA) is generally observed in young male patients but can be diagnosed in older patients. These cases correspond to late-onset SpA (LoSpA) with two main clinical presentations, axial and peripheral SpA. Another increasingly common situation is that of older patients who have had SpA for many years. The therapeutic management of LoSpA is quite smilar to the management of patients with an early-onset disease, combining both non-pharmacological and pharmacological treatments. The treatments that can be used in LoSpA include non-steroidal anti-inflammatory drugs (NSAIDs) and biological agents targeting TNFα or IL-17A...
October 30, 2023: Drugs & Aging
https://read.qxmd.com/read/37864770/prevalence-of-and-risk-factors-for-drug-related-readmissions-in-older-adults-a-systematic-review-and-meta-analysis
#38
Narisha Prasad, Edward C Y Lau, Ilsa Wojt, Jonathan Penm, Zhaoli Dai, Edwin C K Tan
BACKGROUND: Older adults are at an increased risk of drug-related problems, especially following discharge from hospital. Drug-related readmissions place a large burden on the patient and the healthcare system. However, previous studies report inconsistent results on the prevalence and associated risk factors for drug-related hospital readmissions in older adults. OBJECTIVES: We aimed to assess the prevalence of drug-related readmissions in older adults aged 65 years and older and investigate the drug classes, preventability and risk factors most associated with these readmissions...
October 21, 2023: Drugs & Aging
https://read.qxmd.com/read/37863868/prescribing-cascades-with-recommendations-to-prevent-or-reverse-them-a-systematic-review
#39
REVIEW
Oriane Adrien, Atiya K Mohammad, Jacqueline G Hugtenburg, Lisa M McCarthy, Simone Priester-Vink, Robbert Visscher, Patricia M L A van den Bemt, Petra Denig, Fatma Karapinar-Carkıt
BACKGROUND: To reduce prescribing cascades occurring in clinical practice, healthcare providers require information on the prescribing cascades they can recognize and prevent. OBJECTIVE: This systematic review aims to provide an overview of prescribing cascades, including dose-dependency information and recommendations that healthcare providers can use to prevent or reverse them. METHODS: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) was followed...
October 20, 2023: Drugs & Aging
https://read.qxmd.com/read/37863867/anti-vegf-drugs-in-age-related-macular-degeneration-a-focus-on-dosing-regimen-related-safety-and-efficacy
#40
REVIEW
Haibei Ma, Hai Wei, Chunpu Zou, Guoqin Zhu, Qi Gao, Ning Zhang, Bing Wang
Age-related macular degeneration (AMD) is one of the main causes of visual impairment and severe visual loss, and can progress to two advanced forms-neovascularization and atrophic. The field of anti-AMD drugs has undergone huge developments in recent years, from single-target intravitreal administration to current clinical studies with multi-target and non-invasive agents, offering interesting new pharmacological opportunities for the treatment of this disease. Hence, we summarize some of the approved anti-vascular endothelial growth factor (VEGF) drugs for neovascular AMD, especially their structural characteristics, clinical manifestations, dosing regimens, and safety issues of the anti-VEGF drugs highlighted...
October 20, 2023: Drugs & Aging
journal
journal
30642
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.